Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE known ✓ | P06276 | 3/20 | 0.70 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.70 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.70 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.68 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.68 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.76 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.76 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 5/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | RAC1 | P63000 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | GMNN | O75496 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitidine SCHEMBL420918 | 0.99 | BCL2L1 (0.78) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Nitidine SCHEMBL31273992 | 0.99 | BCL2L1 (0.78) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Nitidine SCHEMBL31539472 | 0.98 | BCL2L1 (0.80) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Nitidine SCHEMBL8014101 | 0.98 | BCL2L1 (0.80) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| SCHEMBL11749304 | 0.90 | BCL2L1 (0.68) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| SCHEMBL13170174 | 0.87 | BCL2L1 (1.00) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| SCHEMBL13839324 | 0.84 | RAD52 (0.81) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Chelerythrine SCHEMBL4016265 | 0.82 | ALDH1A1 (0.98) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Chelerythrine SCHEMBL30207103 | 0.82 | ALDH1A1 (1.00) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Chelerythrine SCHEMBL195109 | 0.82 | ALDH1A1 (1.00) | BCL2L1MCL1BAK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 830 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605323-B2 | Composition for inhibiting hair graying, and use thereof | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2026-04-21 | — | — | US | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| CN-118948852-B | Cetirizine hydrochloride oral liquid, preparation process and application | 常州市儿童医院(常州市第六人民医院) | 2025-05-27 | — | — | CN | claimed |
| CN-119569966-A | Preparation method and application of rosin-based chloridized nitine molecularly imprinted polymer | 广西民族大学 | 2025-03-07 | — | — | CN | claimed |
| WO-2024220575-A2 | REGULATING DISEASE OR DISORDER CHARACTERIZED BY ESOPHAGEAL EPITHELIAL PROLIFERATION THROUGH SECRETED FRIZZLED-RELATED PROTEIN 1 (SFRP1) | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-10-24 | — | — | WO | claimed |
| CN-118671253-A | Establishment of HPLC fingerprint spectrum of crude alkaloid in radix zanthoxyli and anti-leukemia activity spectrum effect analysis method | 贵州省天然产物研究中心 | 2024-09-20 | — | — | CN | claimed |
| CN-118275592-A | Quality detection method for Yao medicine mountain tiger | 广西中医药大学 | 2024-07-02 | — | — | CN | claimed |
| CN-118275591-A | Establishment of HPLC fingerprint of Yao medicine Hushanhu and basic source identification method | 广西中医药大学 | 2024-07-02 | — | — | CN | claimed |
| CN-114236034-B | Method for detecting asiatic toddalia root blood medicinal material | 贵州恒霸药业有限责任公司 | 2024-03-29 | — | — | CN | claimed |
| EP-1667743-B1 | BIOCOMPATIBLE, BIOSTABLE COATING OF MEDICAL SURFACES | HEMOTEQ AG (DE) | 2008-01-02 | — | — | EP | claimed |
| EP-1501565-B1 | COMPOUNDS AND METHOD FOR COATING SURFACES IN A HAEMOCOMPATIBLE MANNER | HEMOTEQ GMBH (DE) | 2006-11-02 | — | — | EP | claimed |
| CN-1823975-A | Preparation for treating hysteritis and its quality control method | YE YAOLIANG (CN) | 2006-08-30 | — | — | CN | claimed |
| CN-1799588-A | Chinese medicinal soft capsule, its preparation process and quality control method | ZHANG HONG (CN) | 2006-07-12 | — | — | CN | claimed |
| CN-1733105-A | Preparation for treating gynecological disease, its preparation process and quality control method | GUIYANG YUNYAN XICHUANG PHARM (CN) | 2006-02-15 | — | — | CN | claimed |
| CN-1712051-A | Quality control of Gongyanping preparation | YE YAOLIANG (CN) | 2005-12-28 | — | — | CN | claimed |
| US-20050176678-A1 | Oligosaccharide or polysaccharide which contain sugar segments; antiproliferative agents; antiinflammatory agents; anticoagulants | HEMOTEQ AG (DE) | 2005-08-11 | — | — | US | claimed |
| US-20050129731-A1 | Biocompatible, biostable coating of medical surfaces | HEMOTEQ AG (DE) | 2005-06-16 | — | — | US | claimed |
| US-20050060028-A1 | Blood biocompatible layer and adjacent layer containing antiproliferative, antiinflammatory and/or antithrombotic active agent covalently and/or adhesively bound | HEMOTEQ AG (DE) | 2005-03-17 | — | — | US | claimed |
| CN-1568166-A | Coated stent for preventing restenosis | HEMOTEQ GMBH (DE) | 2005-01-19 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176678-A1 | Oligosaccharide or polysaccharide which contain sugar segments; antiproliferative agents; antiinflammatory agents; anticoagulants | FUT5, CSGALNACT1, FUT6 | BCHE 3017/4885ACHE 2263/4885PRKCE 4530/4885 |
| US-12605323-B2 | Composition for inhibiting hair graying, and use thereof | CTNND1, CTNNB1, GSK3B | BCHE 3882/4885ACHE 2416/4885PRKCE 986/4885 |
| US-20050129731-A1 | Biocompatible, biostable coating of medical surfaces | MSR1, CD44, PIGS | BCHE 857/4885ACHE 3028/4885PRKCE 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.